<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35334234</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>465</StartPage><EndPage>479</EndPage><MedlinePgn>465-479</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(21)00414-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(21)00414-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a fatal neurodegenerative disease. The discovery of genes associated with amyotrophic lateral sclerosis, commencing with SOD1 in 1993, started fairly gradually. Recent advances in genetic technology have led to the rapid identification of multiple new genes associated with the disease, and to a new understanding of oligogenic and polygenic disease risk. The overlap of genes associated with amyotrophic lateral sclerosis with those of other neurodegenerative diseases is shedding light on the phenotypic spectrum of neurodegeneration, leading to a better understanding of genotype-phenotype correlations. A deepening knowledge of the genetic architecture is allowing the characterisation of the molecular steps caused by various mutations that converge on recurrent dysregulated pathways. Of crucial relevance, mutations associated with amyotrophic lateral sclerosis are amenable to novel gene-based therapeutic options, an approach in use for other neurological illnesses. Lastly, the exposome-the summation of lifetime environmental exposures-has emerged as an influential component for amyotrophic lateral sclerosis through the gene-time-environment hypothesis. Our improved understanding of all these aspects will lead to long-awaited therapies and the identification of modifiable risks factors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, and Department of Neurology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf3;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelieff</LastName><ForeName>Masha G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA. Electronic address: efeldman@umich.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AL-CHALABI/APR15/844-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 TS000327</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS120926</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS127188</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 May;21(5):400-401</RefSource><PMID Version="1">35334235</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 Sep;21(9):771-772</RefSource><PMID Version="1">35963253</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 Sep;21(9):772</RefSource><PMID Version="1">35963254</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests SAG declares consulting fees from Biogen and ITF Pharma, a patent &#x201c;Methods for treating amyotrophic lateral sclerosis&#x201d;, and participation on a Data Safety Monitoring Board for Watermark. OH declares consulting fees from Novartis, Cytokinetics, Denali Pharma, Stitching Foundation, and La Caixa; payment or honoraria from Biogen; participation on a Data Safety Monitoring Board for Accelsiors and steering committee for Cytokinetics; and is Editor-in-Chief for the journal Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. AA-C declares consulting fees from Mitsubishi Tanabe Pharma, Biogen Idec, Cytokinetics, Wave Pharmaceuticals, Apellis, Amylyx, Novartis, and Eli Lilly. AC declares grants from Biogen to his institution, payments or honoraria from Biogen and Amylyx, and participation on a Data Safety Monitoring Board for Ely Lilly and ABScience and advisory board for Mitsubishi Tanabe, Roche, Denali Pharma, Cytokinetics, Biogen, and Amylyx. MCK has an honorary role as President of the Brain Foundation and as Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry. ELF declares a patent &#x201c;Methods for treating amyotrophic lateral sclerosis&#x201d;. MGS declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35334234</ArticleId><ArticleId IdType="mid">NIHMS1833665</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pii">S1474-4422(21)00414-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum (Minneap Minn). 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1332&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2019;76(11):1367&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97(6):1268&#x2013;83 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, Doherty MA, Davis N, Corr EM, Vajda A, et al. Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016. Neurol Genet. 2018;4(3):e239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961194</ArticleId><ArticleId IdType="pubmed">29845113</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Hardiman O. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2012;83(4):365&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22399794</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered. 2011;71(4):281&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21846995</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, et al. Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74(12):1425&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822189</ArticleId><ArticleId IdType="pubmed">29049464</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016;87(8):821&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27093948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Chen KS, Paez-Colasante X, Feldman EL. Emerging understanding of the genotype-phenotype relationship in amyotrophic lateral sclerosis. Handb Clin Neurol. 2018;148:603&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29478603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Fagegaltier D, Phatnani H, Harms MB. Genetics of Amyotrophic Lateral Sclerosis. Current Genetic Medicine Reports. 2020;8(4):121&#x2013;31.</Citation></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, McLaughlin RL, Hardiman O, Bradley DG. Using reference databases of genetic variation to evaluate the potential pathogenicity of candidate disease variants. Hum Mutat. 2013;34(6):836&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23447461</ArticleId></ArticleIdList></Reference><Reference><Citation>http://rshiny.tchpc.tcd.ie/users/dohertm7/journALS/App/ [</Citation></Reference><Reference><Citation>McCann EP, Henden L, Fifita JA, Zhang KY, Grima N, Bauer DC, et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32409511</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, McLaughlin RL, Byrne S, Elamin M, Heverin M, Kenny EM, et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. J Med Genet. 2013;50(11):776&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812897</ArticleId><ArticleId IdType="pubmed">23881933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Misawa K, Tohnai G, Nakatochi M, Furuhashi S, Atsuta N, et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun Biol. 2020;3(1):526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Yang W, Wei Q, Shang H. Causal Association of Leukocytes Count and Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study. Mol Neurobiol. 2020;57(11):4622&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32770314</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nature reviews Neurology. 2013;9(11):617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81(12):1324&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1043&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW, Lank RJ, Belzil VV. An Epigenetic Spin to ALS and FTD. Adv Neurobiol. 2018;20:1&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">29916014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Zhang S, Kenna KP, Moll T, Franklin JP, Allen S, et al. Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Rep. 2020;33(9):108456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7710676</ArticleId><ArticleId IdType="pubmed">33264630</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Mazzini L, D&#x2019;Alfonso S, Corrado L, Canosa A, Moglia C, et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology. 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Higashihara M, Sobue G, Atsuta N, Doi Y, Kuwabara S, et al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology. 2020;94(15):e1657&#x2013;e63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251515</ArticleId><ArticleId IdType="pubmed">32071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton FC, Trabjerg BB, Wray NR, Agerbo E. Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis. Eur J Neurol. 2021;28(2):421&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32978838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Hardiman O. Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):232&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">29214883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Ahmed RM, Huynh W, Tu S, Rohrer JD, Bedlack RS, et al. Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs. 2021;35(5):483&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">33993457</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukic S, McMackin R, Buxo T, Fasano A, Chipika R, Pinto-Grau M, et al. Patterned functional network disruption in amyotrophic lateral sclerosis. Hum Brain Mapp. 2019;40(16):4827&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6852475</ArticleId><ArticleId IdType="pubmed">31348605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pender N, Pinto-Grau M, Hardiman O. Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33(5):649&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">32833751</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu S, Menke RAL, Talbot K, Kiernan MC, Turner MR. Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(12):1250&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30049750</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):e1370&#x2013;e80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, D&#x2019;Ovidio F, Vasta R, et al. ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology. 2020;94(8):e802&#x2013;e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11(3):232&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali CP, Patino M, Tai YK, Ho WY, McLean CA, Morris CM, et al. C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. 2019;138(5):795&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802287</ArticleId><ArticleId IdType="pubmed">31327044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology. 2014;82(4):292&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan R, Chia R, Ding J, Hickman RA, Stein TD, Abramzon Y, et al. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron. 2021;109(3):448&#x2013;60 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864894</ArticleId><ArticleId IdType="pubmed">33242422</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme T, Hernandez D, Ross OA, Kun-Rodrigues C, Darwent L, Shepherd CE, et al. Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathol Commun. 2020;8(1):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990558</ArticleId><ArticleId IdType="pubmed">31996268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghahremani Nezhad H, Franklin JP, Alix JJP, Moll T, Pattrick M, Cooper-Knock J, et al. Simultaneous ALS and SCA2 associated with an intermediate-length ATXN2 CAG-repeat expansion. Amyotroph Lateral Scler Frontotemporal Degener. 2020:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33284045</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuenschwander AG, Thai KK, Figueroa KP, Pulst SM. Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. JAMA Neurol. 2014;71(12):1529&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939089</ArticleId><ArticleId IdType="pubmed">25285812</ArticleId></ArticleIdList></Reference><Reference><Citation>Antenora A, Rinaldi C, Roca A, Pane C, Lieto M, Sacc&#xe0; F, et al. The Multiple Faces of Spinocerebellar Ataxia type 2. Ann Clin Transl Neurol. 2017;4(9):687&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5590519</ArticleId><ArticleId IdType="pubmed">28904990</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, et al. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Ann Neurol. 2018;84(1):51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119489</ArticleId><ArticleId IdType="pubmed">29908077</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR. Psychiatric disorders in C9orf72 kindreds: Study of 1,414 family members. Neurology. 2018;91(16):e1498&#x2013;e507.</Citation><ArticleIdList><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>McHutchison CA, Leighton DJ, McIntosh A, Cleary E, Warner J, Porteous M, et al. Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. J Neurol Neurosurg Psychiatry. 2020;91(3):245&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">31871139</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Tu S, Caga J, Ahmed RM, Ramsey E, Zoing M, et al. Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS-FTD spectrum. Ann Clin Transl Neurol. 2021;8(8):1576&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351398</ArticleId><ArticleId IdType="pubmed">34156763</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin RL, Schijven D, van Rheenen W, van Eijk KR, O&#x2019;Brien M, Kahn RS, et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat Commun. 2017;8:14774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364411</ArticleId><ArticleId IdType="pubmed">28322246</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CP, Li X, Wu Y, Shen Q, Zeng Y, Xiong Q, et al. Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nat Commun. 2018;9(1):838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826945</ArticleId><ArticleId IdType="pubmed">29483533</ArticleId></ArticleIdList></Reference><Reference><Citation>McMackin R, Dukic S, Costello E, Pinto-Grau M, McManus L, Broderick M, et al. Cognitive network hyperactivation and motor cortex decline correlate with ALS prognosis. Neurobiol Aging. 2021;104:57&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">33964609</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: A review. Mol Ther. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">29192260</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34(6):404&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci U S A. 2019;116(10):4696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A, Gurfinkel Y, Polain N, Lamont W, Lyn Rea S. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD. Int J Mol Sci. 2021;22(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9(10):995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll T, Shaw PJ, Cooper-Knock J. Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration. Brain. 2020;143(5):1332&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241952</ArticleId><ArticleId IdType="pubmed">31724708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP. Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. Neuron. 2017;96(2):285&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21(2):228&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Kumar MS, Ramesh N, Anderson EN, Nguyen AT, Kim B, et al. Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nat Neurosci. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832378</ArticleId><ArticleId IdType="pubmed">34059832</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Yamashita T, Nakano Y, Morihara R, Li X, Feng T, et al. Aberrant distributions of nuclear pore complex proteins in ALS mice and ALS patients. Neuroscience. 2017;350:158&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28344074</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, et al. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer&#x2019;s Disease. Neuron. 2018;99(5):925&#x2013;40.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, et al. Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. Neuron. 2017;94(1):48&#x2013;57.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science. 2019;363(6428).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Wu Y, Odeh HM, Gendron TF, Jansen-West K, Del Rosso G, et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med. 2020;12(559).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, Hartmann H, May S, M&#xf6;hl C, Ederle H, Michaelsen M, et al. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. Hum Mol Genet. 2017;26(4):790&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409121</ArticleId><ArticleId IdType="pubmed">28040728</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, et al. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135(3):459&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakravan D, Orlando G, Bercier V, Van Den Bosch L. Role and therapeutic potential of liquid-liquid phase separation in amyotrophic lateral sclerosis. J Mol Cell Biol. 2021;13(1):15&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8036000</ArticleId><ArticleId IdType="pubmed">32976566</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Kovacs D, Konijnenberg A, Timmerman E, Volkov A, et al. Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Mol Cell. 2017;65(6):1044&#x2013;55.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, et al. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron. 2019;102(2):339&#x2013;57.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E, Grad LI, Cashman NR. TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion. Sci Rep. 2016;6:22155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772009</ArticleId><ArticleId IdType="pubmed">26926802</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, LaClair KD, Riemenschneider H, Zhou Q, Frottin F, Mareljic N, et al. Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD. Embo j. 2020;39(8):e102811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156967</ArticleId><ArticleId IdType="pubmed">32175624</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, et al. Cell-to-Cell Transmission of Dipeptide Repeat Proteins Linked to C9orf72-ALS/FTD. Cell Rep. 2016;17(3):645&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078984</ArticleId><ArticleId IdType="pubmed">27732842</ArticleId></ArticleIdList></Reference><Reference><Citation>Sackmann C, Sackmann V, Hallbeck M. TDP-43 Is Efficiently Transferred Between Neuron-Like Cells in a Manner Enhanced by Preservation of Its N-Terminus but Independent of Extracellular Vesicles. Front Neurosci. 2020;14:540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301158</ArticleId><ArticleId IdType="pubmed">32595443</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. Cytotoxic CD8(+) T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A. 2019;116(6):2312&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O&#x2019;Rourke JG, Y&#xe1;&#xf1;ez A, Markman JL, Ho R, Wang X, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585(7823):96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183(3):636&#x2013;49.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74(12):1446&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Famie JP, Piecuch CE, Raue KD, Mendelson FE, Pieroni CH, et al. Natural killer cells associate with amyotrophic lateral sclersois in a sex- and age-dependent manner. JCI Insight. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. The Lancet Neurology. 2014;13(11):1108&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MD, Little J, Gomes J, Cashman NR, Krewski D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology. 2017;61:101&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27377857</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Glascow N, Barry ADF, Moll T, Harvey C, Klimentidis YC, et al. Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine. 2021;68:103397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Feldman EL. Voicing the Need for Amyotrophic Lateral Sclerosis Environmental Research. JAMA neurology. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7977264</ArticleId><ArticleId IdType="pubmed">32119032</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(8):907&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625908</ArticleId><ArticleId IdType="pubmed">30760645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Lv X, Du H, Wu D, Wang M. Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study. Prog Neuropsychopharmacol Biol Psychiatry. 2020;97:109771.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669200</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, Pradat PF, Querin G, Delbot F, Le Chat G, Pradat-Peyre JF, et al. Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. Front Neurosci. 2019;13:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6403867</ArticleId><ArticleId IdType="pubmed">30872992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bean DM, Al-Chalabi A, Dobson RJB, Iacoangeli A. A Knowledge-Based Machine Learning Approach to Gene Prioritisation in Amyotrophic Lateral Sclerosis. Genes (Basel). 2020;11(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349022</ArticleId><ArticleId IdType="pubmed">32575372</ArticleId></ArticleIdList></Reference><Reference><Citation>Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">30846871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1713&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455913</ArticleId><ArticleId IdType="pubmed">30166482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390938</ArticleId><ArticleId IdType="pubmed">30010673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CKW, Gapinske M, Brooks AK, Woods WS, Powell JE, Zeballos CM, et al. Treatment of a Mouse Model of ALS by In Vivo Base Editing. Mol Ther. 2020;28(4):1177&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3(12):eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>